Arvinas 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   2 Trials   198 News 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bavdegalutamide (ARV-110) / Arvinas
ARDENT, NCT03888612: Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Checkmark Safety data from trial for metastatic castration-resistant prostate cancer
Oct 2019 - Oct 2019: Safety data from trial for metastatic castration-resistant prostate cancer
Active, not recruiting
1/2
250
US
ARV-110
Arvinas Inc.
Prostate Cancer Metastatic
04/24
11/24
NCT05177042: Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Active, not recruiting
1
40
Europe, Canada, US
ARV-110 in Combination with Abiraterone
Arvinas Androgen Receptor, Inc.
Prostate Cancer Metastatic
07/24
12/25
vepdegestrant (ARV-471) / Arvinas, Pfizer
VERITAC-2, NCT05654623: A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Recruiting
3
560
Europe, Canada, Japan, US, RoW
ARV-471, PF-07850327, Fulvestrant
Pfizer, Arvinas Estrogen Receptor, Inc.
Advanced Breast Cancer
11/24
05/28
VERITAC-3, NCT05909397: A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer

Active, not recruiting
3
1180
Europe, Japan, US, RoW
ARV-471 (PF-07850327), Vepdegestrant, Palbociclib, IBRANCE®, Letrozole, FEMARA®
Pfizer, Arvinas Estrogen Receptor, Inc.
Breast Cancer
08/28
07/30
2021-005081-17: A Phase 2 trial using ARV-471 or Anastrozole in Post-Menopausal Women with Breast Cancer Prior to Surgery.

Not yet recruiting
2
150
Europe
ARV-471, Anastrozole, ARV-471, Tablet, Film-coated tablet, Anastrozole Teva
Arvinas Estrogen Receptor, Inc. (Arvinas), Arvinas Estrogen Receptor, Inc. (Arvinas)
Post-menopausal women with ER+ HER2– breast cancer, Breast cancer in post-menopausal women, Diseases [C] - Cancer [C04]
 
 
TACTIVE-N, NCT05549505: A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Completed
2
152
Europe, US, RoW
ARV-471, Anastrozole, Arimidex, Surgical resection of breast tumor
Arvinas Inc., Pfizer
Breast Cancer
07/24
07/24
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
TACTIVE-K, NCT06206837: A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Recruiting
1/2
65
Europe, Canada, Japan, US, RoW
vepdegestrant, ARV-471 / PF07850327, PF-07220060
Pfizer, Arvinas Estrogen Receptor, Inc.
Breast Cancer
08/25
02/26
VERITAC, NCT04072952: A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Checkmark Data for locally adv/met ER+ / HER2- breast cancer
Dec 2020 - Dec 2020: Data for locally adv/met ER+ / HER2- breast cancer
Active, not recruiting
1/2
217
US
ARV-471, ARV-471 in combination with palbociclib (IBRANCE®)
Arvinas Estrogen Receptor, Inc., Pfizer
Breast Cancer
09/24
03/25
TACTIVE-U Sub-Study A, NCT05548127: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Active, not recruiting
1/2
37
Europe, Canada, US
ARV-471, vepdegestrant, PF-07850327, Abemaciclib
Pfizer, Arvinas Estrogen Receptor, Inc.
Breast Cancer
09/25
09/25
TACTIVE-U Sub-Study B, NCT05573555: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Recruiting
1/2
47
Europe, Canada, US
ARV-471, Ribociclib
Pfizer, Arvinas Estrogen Receptor, Inc.
Breast Cancer
01/27
01/27
C4891024, NCT06125522: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

Recruiting
1/2
67
Europe, Canada, US
vepdegestrant, ARV-471 / PF-07850327, Samuraciclib
Pfizer, Arvinas Estrogen Receptor, Inc., Carrick Therapeutics Limited
Breast Cancer
07/26
01/27
NCT05652660: A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

Completed
1
12
US
ARV-471, PF-07850327, Rosuvastatin, CRESTOR®
Pfizer, Arvinas Estrogen Receptor, Inc.
Healthy
02/23
03/23
NCT05673889: A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults

Completed
1
24
Europe
ARV-471, PF-07850327, Dabigatran etexilate, PRADAXA®
Pfizer, Arvinas Estrogen Receptor, Inc.
Healthy
03/23
04/23
NCT05463952: A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

Active, not recruiting
1
6
Japan
vepdegestrant, ARV-471, PF-07850327
Pfizer, Arvinas Estrogen Receptor, Inc.
Breast Neoplasms
05/23
03/25
NCT05538312: A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults

Completed
1
12
Europe
vepdegestrant, ARV-471, PF-07850327, Itraconazole, Sporanox
Pfizer, Arvinas Estrogen Receptor, Inc.
Healthy
04/23
05/23
NCT05930925: A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

Completed
1
12
US
[phenyl-14C]ARV-471, [oxoisoindolin-14C]ARV-471
Pfizer, Arvinas Estrogen Receptor, Inc.
Healthy
07/23
08/23
PK, NCT06005688: A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants

Completed
1
12
Europe
Vepdegestrant, ARV-471, PF-07850327, Carbamazepine, Tegretol
Pfizer, Arvinas Estrogen Receptor, Inc.
Healthy Participants
10/23
11/23
NCT05732428: A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China

Active, not recruiting
1
9
RoW
ARV-471
Pfizer, Arvinas Estrogen Receptor, Inc.
Breast Cancer
03/24
11/24
C4891039, NCT06256510: A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

Completed
1
15
Europe
Midazolam, Vepdegestrant, ARV-471, PF-07850327
Pfizer, Arvinas Estrogen Receptor, Inc.
Healthy Participants
04/24
05/24
NCT06275841: A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Completed
1
12
US
vepdegestrant, esomeprazole
Pfizer, Arvinas Estrogen Receptor, Inc.
Healthy
05/24
05/24
NCT06347861: A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

Completed
1
52
US
single dose of vepdegestrant as tablet formulation (Treatment A), ARV-471, PF-07850327, single dose of vepdegestrant as tablet formulation (Treatment B), single dose of vepdegestrant as tablet formulation (Treatment C)
Pfizer, Arvinas Estrogen Receptor, Inc.
Healthy
07/24
08/24
TACTIVE-E, NCT05501769: ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

Active, not recruiting
1
32
Europe, US
ARV-471 in combination with Everolimus
Arvinas Estrogen Receptor, Inc., Pfizer
Breast Cancer
07/24
11/24
C4891038, NCT06645938: A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults.

Not yet recruiting
1
12
NA
single dose of vepdegestrant as tablet formulation (Treatment A), ARV-471, PF-07850327, single dose of vepdegestrant as tablet formulation (Treatment B)
Pfizer, Arvinas Estrogen Receptor, Inc.
Healthy
12/24
12/24
luxdegalutamide (ARV-766) / Novartis
ARV-766-mCRPC-101, NCT05067140: A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Recruiting
1/2
220
US
ARV-766 Part A&B, ARV-766 + Abiraterone Part C&D, Corticosteroid and ADT
Arvinas Androgen Receptor, Inc.
Prostate Cancer Metastatic
12/25
06/26
ARV-393 / Arvinas
ARV-393-101, NCT06393738: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Recruiting
1
112
Europe, Canada, US
ARV-393
Arvinas Inc.
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
12/25
12/25
Myelocytomatosis protein degrader / Arvinas
No trials found
Undisclosed KRAS G12V-specific PROTAC degrader / Arvinas
No trials found
Undisclosed KRAS G12D-specific PROTAC degrader / Arvinas
No trials found
Undisclosed HPK1 degrader / Arvinas
No trials found
Undisclosed PROTAC degrader / Arvinas, Bayer
No trials found
Undisclosed anticancer therapeutic / Arvinas
No trials found
Undisclosed alpha synuclein inhibitor / Arvinas
No trials found
A947 / Arvinas, Roche
No trials found

Download Options